美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Faeth Therapeutics

35.37

-3.7200-9.52%

成交量：20.94萬

成交額：766.62萬

市值：9.12億

市盈率：-0.25

高：39.89

開：38.75

低：34.88

收：39.09

52周最高：42.14

52周最低：7.45

股本：2,577.88萬

流通股本：81.17萬

量比：0.68

換手率：25.80%

股息：- -

股息率：- -

每股收益(TTM):-141.6499

每股收益(LYR):-16.7239

淨資產收益率：-195.26%

總資產收益率：-20.79%

市淨率：5.27

市盈率(LYR):-2.11

資料載入中...

總覽公司新聞資訊公告

FDA授予抗癌藥物快速通道資格後，Faeth Therapeutics股價上漲

Faeth Therapeutics：晚期子宮內膜癌2期試驗頂線數據預計2026年底公布

美國研究綜述-美國鐵塔公司、H.B.富勒公司、TD Synnex

Sensei Biotherapeutics：Piktor治療HR+/HER2-晚期乳腺癌的1B/2期中期數據預計2027年公布

Sensei Biotherapeutics：Piktor治療晚期子宮內膜癌的II期關鍵數據預計2026年下半年公布

Sensei Biotherapeutics任命Anand Parikh為董事長、總裁兼首席執行官，自2026年6月12日起生效

Sensei Biotherapeutics更名為Faeth Therapeutics，全力推進口服抗癌療法Piktor

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/FTH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"FTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FTH\",,,,,undefined,":{"symbol":"FTH","market":"US","secType":"STK","nameCN":"Faeth Therapeutics","latestPrice":35.37,"timestamp":1789502400000,"preClose":39.09,"halted":0,"volume":209394,"delay":0,"changeRate":-0.09516500383729869,"floatShares":811700,"shares":25778800,"eps":-141.6499,"marketStatus":"盤前交易","change":-3.72,"latestTime":"09-16 05:17:50 EDT","open":38.75,"high":39.89,"low":34.88,"amount":7666233.875244,"amplitude":0.128166,"askPrice":43.2,"askSize":100,"bidPrice":35.37,"bidSize":46,"shortable":0,"etf":0,"ttmEps":-141.6499,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789565400000},"marketStatusCode":1,"adr":0,"listingDate":1612414800000,"exchange":"NASDAQ","adjPreClose":35.37,"postHourTrading":{"tag":"盘后","latestPrice":35.88,"preClose":35.37,"latestTime":"19:53 EDT","volume":358,"amount":12833.5401,"timestamp":1789516430954,"change":0.51,"changeRate":0.014419,"amplitude":0.014419},"volumeRatio":0.675028143118933},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FTH\",,,,,undefined,":{"symbol":"FTH","floatShares":811700,"roa":"-20.79%","roe":"-195.26%","lyrEps":-16.72388,"volumeRatio":0.675028143118933,"shares":25778800,"dividePrice":0,"high":39.89,"amplitude":0.128166,"preClose":39.09,"low":34.88,"week52Low":7.45,"pbRate":"5.27","week52High":42.1431,"institutionHeld":0,"latestPrice":35.37,"committee":-0.369863,"eps":-141.6499,"divideRate":0,"volume":209394,"delay":0,"ttmEps":-141.6499,"open":38.75,"prevYearClose":10.67,"prevWeekClose":37.44,"prevMonthClose":32.77,"prevQuarterClose":25,"fiveDayClose":39.2,"twentyDayClose":32.77,"sixtyDayClose":17.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FTH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"FTH","fiscalQuarterEnding":"2026/06","expectedEps":-1.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-2.84},{"market":"US","date":"2026-05-15","symbol":"FTH","fiscalQuarterEnding":"2026/03","expectedEps":-0.62,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-131.45},{"market":"US","date":"2026-03-30","symbol":"FTH","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-3.74},{"market":"US","date":"2025-11-14","symbol":"FTH","fiscalQuarterEnding":"2025/09","expectedEps":-4.11,"name":null,"time":"盤前","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-3.62},{"market":"US","date":"2025-08-05","symbol":"FTH","fiscalQuarterEnding":"2025/06","expectedEps":-6.2,"name":null,"time":"盤前","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"pre","actualEps":-3.91}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FTH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FTH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.5833,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1789012800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FTH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FTH","date":"2026-09-14","current":-0.2497,"percent":0.101695,"low":-5.292894,"twenty":-4.561008,"median":-3.985108,"eighty":-3.360395,"high":-0.105707,"avg":-3.827199,"sd":1.140745,"marketCap":967465512},"quantilePoints":[{"date":"2026-06-18","current":-0.12113,"twenty":-0.118045,"median":-0.113419,"eighty":-0.108792,"marketCap":22343317},{"date":"2026-06-26","current":-3.447751,"twenty":-3.41449,"median":-0.168709,"eighty":-0.122832,"marketCap":635961861},{"date":"2026-07-02","current":-3.306599,"twenty":-3.429583,"median":-3.245107,"eighty":-0.129642,"marketCap":609925319},{"date":"2026-07-10","current":-4.547622,"twenty":-3.49387,"median":-3.330357,"eighty":-0.168709,"marketCap":838840655},{"date":"2026-07-17","current":-3.62524,"twenty":-4.398084,"median":-3.429583,"eighty":-3.196193,"marketCap":668700878},{"date":"2026-07-24","current":-3.879594,"twenty":-4.005373,"median":-3.554664,"eighty":-3.20318,"marketCap":715618211},{"date":"2026-07-31","current":-4.027734,"twenty":-4.074133,"median":-3.637119,"eighty":-3.236722,"marketCap":742943690},{"date":"2026-08-07","current":-3.227486,"twenty":-4.048697,"median":-3.62524,"eighty":-3.239088,"marketCap":631063897},{"date":"2026-08-14","current":-3.773087,"twenty":-4.030809,"median":-3.711043,"eighty":-3.239088,"marketCap":737744133},{"date":"2026-08-21","current":-4.242245,"twenty":-4.248589,"median":-3.806921,"eighty":-3.244483,"marketCap":829477642},{"date":"2026-08-28","current":-4.458983,"twenty":-4.358015,"median":-3.881185,"eighty":-3.294301,"marketCap":871855939},{"date":"2026-09-04","current":-5.154129,"twenty":-4.410264,"median":-3.939688,"eighty":-3.344613,"marketCap":1007776575},{"date":"2026-09-11","current":-5.154129,"twenty":-4.552871,"median":-3.964844,"eighty":-3.358825,"marketCap":1007776575},{"date":"2026-09-14","current":-4.947964,"twenty":-4.561008,"median":-3.985108,"eighty":-3.360395,"marketCap":967465512}],"updateTime":1789528486797},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FTH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660448760","title":"FDA授予抗癌藥物快速通道資格後，Faeth Therapeutics股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448760","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660448760?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 20:19","pubTimestamp":1786969153,"startTime":"0","endTime":"0","summary":"BUZZ-FDA授予抗癌药物快速通道资格后，Faeth Therapeutics股价上涨8月17日-** 抗癌药物开发商 Faeth Therapeutics（FTH.O）的股价在盘前交易中上涨 2%，至 33 美元** 该公司表示，美国食品药品监督管理局（FDA）已授予其实验性双药疗法PIKTOR（联合化疗）快速通道资格，该疗法适用于部分晚期或复发性子宫内膜癌患者，子宫内膜癌是一种起源于子宫内膜","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E0SZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137671951","title":"Faeth Therapeutics：晚期子宮內膜癌2期試驗頂線數據預計2026年底公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1137671951","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137671951?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:33","pubTimestamp":1786966420,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics宣布，其针对晚期子宫内膜癌的2期临床试验顶线数据，预计将于2026年底揭晓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646343783","title":"美國研究綜述-美國鐵塔公司、H.B.富勒公司、TD Synnex","url":"https://stock-news.laohu8.com/highlight/detail?id=2646343783","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646343783?lang=zh_tw&edition=fundamental","pubTime":"2026-06-26 15:07","pubTimestamp":1782457653,"startTime":"0","endTime":"0","summary":"美国研究综述-美国铁塔公司、H.B.富勒公司、TD Synnex路透6月26日-周五，华尔街的证券分析师们调整了多家在美国上市公司的评级和目标股价，其中包括美国铁塔公司、H.B.富勒公司和TD Synnex。重点摘要* 美国铁塔公司AMT.N：加拿大皇家银行将其评级从“行业表现”上调至“跑赢大盘”* H.B.富勒公司 FUL.N：摩根大通将评级从“中性”上调至“超配”* TD SynnexSNX.N：RBC将目标价从315美元上调至340美元以下是路透周五报导的针对美国公司的研究动向摘要。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL4T42Y0EV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0683600562.USD","LU0823417737.USD","LU2023250504.SGD","IE000MB6IJN5.SGD","IE00BSNM7G36.USD","SG9999001176.SGD","LU1066051498.USD","LU0444973449.USD","MUU","BK4567","LU1674673428.USD","LU1868836914.USD","BK4605","SG9999002224.SGD","IE00BQXX3D17.EUR","INR","LU1057294990.SGD","LU2250418816.HKD","ON","IE000BZT7R73.USD","IE00BFMHRM44.USD","LU1046421795.USD","LU1974910355.USD","LU2756315318.SGD","LU0345769631.USD","LU0689626769.HKD","LU0234570918.USD","LU0757428866.USD","LU1935042991.SGD","IE00BJT1NW94.SGD","LU0964807845.USD","LMT","LU1023059063.AUD","ESS","LU0868494708.USD","IE00BQXX3F31.USD","LU0082616367.USD","LU0320765646.SGD","MRNX","LU2592432038.USD","LU0231203729.USD","LU1861215975.USD","LU2347655156.SGD","LU2505996681.GBP","LU1162221912.USD","BK4532","LU1868837300.USD","LU0289960550.SGD","LU1823568750.SGD","LU0345769128.USD","LU2417539215.USD","LU0354030511.USD","BK4554","LU1061106388.HKD","BK4213","BK4588","LU2133065610.SGD","LU1221951129.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU1035775433.USD","LU1244550577.SGD","LU0056508442.USD","IE0034235303.USD","SYNA","LU1778281490.HKD","BK4501","LU2506951958.HKD","SNX","LU1551013342.USD","LU2129689514.USD","LU2896262040.SGD","LU0109392836.USD","PCTY","LU1914381329.SGD","LU2403377893.USD","LU1805238398.USD","IE000SO60NU8.SGD","LU0476273544.USD","LU2290526834.HKD","LU0127658192.USD","LU2458330243.SGD","LU1166156734.SGD","LU2213496289.HKD","LU2458330169.SGD","BK4141","LMTS","LU0553294199.USD","LU1066051225.USD","LU2089984988.USD","LU2360107325.USD","LU1815336091.USD","BK4177","LU2360106780.USD","IE00BZ1G4Q59.USD","LU0444971666.USD","LU0689472784.USD","LU2357627491.SGD","LU0642271901.SGD","SG9999013999.USD","GB00BDT5M118.USD","LU2413666699.HKD","LU0061475181.USD","LU0889566641.SGD","BK4187","JNJ","LU0432979614.USD","IE00B2B36J28.USD","LU0640476718.USD","LU1032955483.USD","BK4219","LU0011850046.USD","BK4548","LU1003077747.HKD","LU2471134523.USD","LU1228905037.USD","LU0347712357.USD","LU0070217475.USD","LU0256331488.USD","LU2468319806.SGD","LU2430703095.HKD","LU2931357623.SGD","BK4527","LU0985320562.USD","BK4551","LU0345770308.USD","LU2298322129.HKD","BK4215","LU2211815571.USD","LU1430594728.SGD","BK4084","LU0072462343.USD","IE00BFXG1179.USD","LU0154245756.USD","LU0795875169.SGD","LU2602419157.SGD","LU1894683264.USD","LU1929549753.HKD","MULL","LU0287143357.SGD","BK4518","SG9999001424.SGD","LU1868836757.USD","LU2543165471.USD","LU1196500208.SGD","IE000M9KFDE8.USD","BK4592","LU0943347566.SGD","MRNY","IE00BBT3K403.USD","IE0000B7K699.USD","LU2236285917.USD","LU1244550221.USD","AR","OVV","LU0124384867.USD","LU1228905540.USD","LU1048596156.SGD","LU1585245621.USD","LU1815336760.USD","AVXX","LU2506951875.HKD","IE00BVYPNW00.USD","LU2487616109.SGD","SG9999002232.USD","LU1983260115.SGD","IE00BKVL7J92.USD","LU2129689431.USD","BK4209","MUD","LU1244550494.USD","IE00B1BXHZ80.USD","LU1721428933.USD","IE00BFTCPJ56.SGD","IE00BLSP4239.USD","LU2129689605.HKD","IE0009356076.USD","LU2023250843.SGD","LU0006061336.USD","AMT","LU2028103732.USD","IE00B7SZLL34.SGD","LU0079474960.USD","BK4585","LU0702159343.USD","SG9999001440.SGD","LU1121112475.USD","SG9999000418.SGD","BK4533","BK4579","LU2106854487.HKD","LU1861214812.USD","LU0820561818.USD","LU0792757196.USD","LU2430703178.SGD","BK4134","LU0820561909.HKD","LU1043141396.HKD","LU1366333091.USD","LU1323610961.USD","BK4139","IE00BK4W5L77.USD","LU0175139822.USD","BK4553","LU1551013425.SGD","IE0002141913.USD","LU0097036916.USD","LU0882574055.USD","LU0210536198.USD","LU2271345857.HKD","LU2089283258.USD","LU1059921491.USD","BK4597","IE00B3PB1722.GBP","LU2023250330.USD","BK4023","LU0114720955.EUR","LU2111349929.HKD","LU0124676726.USD","PEP","BK4550","AVAV","MU","LU2456880835.USD","BK4581","LU0820562030.AUD","LU1316542783.SGD","IE00BN8TJ469.HKD","LU1732799900.SGD","LU0823417653.USD","LU1839511570.USD","BK4109","LU2286300806.USD","LU2756315664.SGD","IE0009355771.USD","LU1803068979.SGD","IE000F7OJYX1.SGD","LU0157215616.USD","BK4604","LU0466842654.USD","KWR","LU0950375773.USD","LU2054465674.USD","LU0426412945.USD","LU1978683503.SGD","LU0795875086.SGD","IE00BK4W5M84.HKD","LU1261432733.SGD","BK4504","BK4559","LU1066051811.HKD","BK4575","IE00BGHQF631.EUR","LU0154245673.USD","BK4130","LU0203345920.USD","LU2087621335.USD","LU0545562505.USD","LU0122379950.USD","LU2048586759.USD","LU2413666426.HKD","LU0158827781.USD","LU0787776722.HKD","BK4512","LU1221951046.USD","LU0234572021.USD","MRNA","LU0081259029.USD","LU1989773731.SGD","LU0957808578.USD","LU0096362180.USD","LU2750360997.AUD","BK4566","LU1854103824.USD","BK4564","LU0868494617.USD","LU0158827948.USD","IE00B4R5TH58.HKD","LU1815333072.USD","LU0354030438.USD","LU1894683348.USD","LU1506573853.SGD","LU0274383776.USD","LU0738911758.USD","LU0545039389.USD","IE00BDGV0183.EUR","LU0238689110.USD","LU0061474960.USD","IE00B42XCP33.USD","LU1074936037.SGD","BK4534","LU1280957306.USD","LU1496350502.SGD","LU2505996509.AUD","SGXZ57979304.SGD","LU2471134952.CNY","LU2471134879.HKD","04336","LU0957791311.USD","IE00BVYPNV92.GBP","LMTL","IE000WAW04H5.SGD","LU0426417589.USD","LU1267930656.SGD","LU2471134796.USD","IE00B5949003.HKD","LU0053666078.USD","LU0719512351.SGD","LU2430703251.USD","LU0197229882.USD","LU0198837287.USD","BK4140","IE00B19Z3B42.SGD","BK4147","LU0702159699.USD","LU1720051017.SGD","LU2112291526.USD","LU0949170772.SGD","BK4516","IE0002270589.USD","LU1069344957.HKD","LU1732800096.USD","LU0821914370.USD","LU1861220033.SGD","LU2357305700.SGD","LU1032466523.USD","LU0098860793.USD","IE00B19Z3581.USD","IE0001KFT4U8.USD","IE00B3T34201.USD","LU0536402901.SGD","LU0724618433.USD","SG9999001176.USD","LU0348723411.USD","LU0942090050.USD","LU0661504455.SGD","LU0154236417.USD","LU0289739699.SGD","LU2023251221.USD","BK4519","BK4603","LU0345770993.USD","LU2089284900.SGD","IE00BQXX3C00.GBP","LU2506952170.USD","LU0994945656.USD","LU2360107168.USD","LU1868836591.USD","LU1720051108.HKD","DRI","LU1868837136.USD","LU2506952097.USD","LU0708995666.HKD","AMAT","LU1145028129.USD","LU1861219969.SGD","IE0034390439.USD","LU1983299246.USD","LU1718418525.SGD","LU0889565833.HKD","LU1674673691.USD","BK4007","CTSH","BK4568","LU0210528500.USD","KYMR","LU1267930813.SGD","LU1852331112.SGD","LU1917777945.USD","BK4543","IE00BD6J9T35.USD","LU1066053197.SGD","LU1642822529.SGD","LU1043141123.HKD","LU0859254822.USD","LU2750360641.GBP","IE00BZ199S13.USD","LU1548497426.USD","LU1048588211.SGD","LU1153585028.USD","LU2089985449.USD","LU1629891620.HKD","FUL","FTH","IE00BLSP4452.SGD","IE00B19Z6F94.USD","LU1854104046.USD","LU0912757837.SGD","LU0096364046.USD","LU0203347892.USD","LU1989763005.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155638133","title":"Sensei Biotherapeutics：Piktor治療HR+/HER2-晚期乳腺癌的1B/2期中期數據預計2027年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1155638133","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155638133?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 20:12","pubTimestamp":1781525543,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics公司宣布，其候选疗法Piktor针对HR阳性、HER2阴性晚期乳腺癌的1B/2期临床试验中期数据，预计将于2027年获得。该数据将提供关于疗法安全性及初步疗效的关键见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNSE","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197135575","title":"Sensei Biotherapeutics：Piktor治療晚期子宮內膜癌的II期關鍵數據預計2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1197135575","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197135575?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 20:12","pubTimestamp":1781525543,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics公司宣布，其候选药物Piktor针对晚期子宫内膜癌的II期临床试验关键性数据，预计将于2026年下半年公布。这一时间表为关注该疗法进展的投资者和医学界提供了明确的时间节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNSE","BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110665123","title":"Sensei Biotherapeutics任命Anand Parikh為董事長、總裁兼首席執行官，自2026年6月12日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1110665123","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110665123?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 20:11","pubTimestamp":1781525508,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics, Inc. (SNSE) 宣布，自2026年6月12日起，Anand Parikh将正式出任公司董事长、总裁兼首席执行官。此项任命标志着公司领导层的重要更迭。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNSE","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139331227","title":"Sensei Biotherapeutics更名為Faeth Therapeutics，全力推進口服抗癌療法Piktor","url":"https://stock-news.laohu8.com/highlight/detail?id=1139331227","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139331227?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525426,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics, Inc. 宣布将公司名称变更为Faeth Therapeutics。这一更名标志着公司战略重心聚焦于推进其核心候选药物Piktor的研发。Piktor是一种口服疗法，旨在靶向癌症中最常发生异常改变的信号通路之一。公司此举旨在更好地反映其专注于开发变革性癌症治疗药物的新方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","SNSE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}